[PDF] Top 20 Una respuesta regional a la (in)seguridad alimentaria
Has 10000 "Una respuesta regional a la (in)seguridad alimentaria" found on our website. Below are the top 20 most common "Una respuesta regional a la (in)seguridad alimentaria".
<p>Cryoablation In The Management Of Breast Cancer: Evidence To Date</p>
... response, which may aid in tumor control and cure. 3,21,43 The key point is that antigenic tissue remains in the breast after local ablation. Cryoablation of tumor lesions causes the coagulative necrosis of ... See full document
52
<p>Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date</p>
... high-quality evidence that improving glycemic control in those with newly established T2D conclusively reduces rates of microvascular complica- tions and long-term macrovascular ... See full document
138
<p>The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date</p>
... vivo evidence regarding SNAC safety and tolerability is still ...this evidence suggested that the use of SNAC as a method of overcoming absorption barriers should be a safe approach, considering that the ... See full document
11
<p>Evidence to date: talazoparib in the treatment of breast cancer</p>
... The pivotal study which led to FDA approval of talazo- parib was the EMBRACA trial. 15 This phase III trial randomized 431 patients (2:1) and compared the ef fi cacy and safety of talazoparib with standard chemotherapy of ... See full document
9
<p>Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date</p>
... liver cancer with a dismal prognosis, especially when diagnosed at advanced ...the management of advanced ...liver cancer, immunotherapy, nivolumab, lenvatinib, ... See full document
12
Tocotrienols and breast cancer: the evidence to date
... Abstract Breast cancer is the second most frequent cancer affecting women worldwide after lung cancer. The toxicity factor associated with synthetic drugs has turned the attention toward ... See full document
28
<p>Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date</p>
... Abstract: Age-related macular degeneration (AMD) is one of the leading causes of blind- ness in older adults worldwide. The advent of intravitreal neutralization of vascular endothe- lial growth factor (VEGF) has ... See full document
10
<p>Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date</p>
... the Management of Dyslipidemia recommend consideration of icosapent ethyl 2x2g/day in combination with a statin in high-risk patients (de fi ned as individuals with documented ASCVD, DM with risk features, moderate ... See full document
9
<p>Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date</p>
... Finasteride is classi fi ed as pregnancy category X, ie, it is contradicted in women who are or may become pregnant. 17 An animal study showed that fi nasteride led to dose-dependent development of hypospadias in male ... See full document
16
<p>Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date</p>
... demonstrated evidence for cardiovascular and mortality benefit of sacubitril/valsartan, a dual angiotensin receptor blocker and nepri- lysin inhibitor (ARNI), over enalapril (an angiotensin-converting enzyme ... See full document
7
<p>Therapeutic Potential of Dupilumab in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Evidence to Date</p>
... Medical management of chronic rhinosinusitis with nasal polyposis addresses the underlying in fl ammation, mucous production, nasal airway obstruction and reduced sense of ... See full document
9
<p>Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date</p>
... primary adverse events noted in these trials include nau- sea, fatigue, vomiting, and anemia. A summary of grade 3 – 4 adverse events is provided in Table 2. 19–22 Rare but serious adverse events associated with olaparib ... See full document
16
<p>Surgical Management Strategy for Breast Cancer Patients During the COVID-19 Outbreak</p>
... COVID-19 is a major public health emergency and is highly contagious. People ’ s psychological pressure tends to increase in such a circumstance. The National Health Committee issued Guidelines for Emergency ... See full document
13
<p>The Exosome And Breast Cancer Cell Plasticity</p>
... of cancer cell pools, activation of facultative cancer stem cells (CSCs), transdifferentiation or dedifferentiation, phe- notypic transition of differentiated cells within a tumor to meet the challenges ... See full document
5
<p>The Prognosis Of Peroxiredoxin Family In Breast Cancer</p>
... However, there are a number of reports suggesting that PRDX1 is likely to play the role of a tumor suppressor in breast cancer. Cao J et al 59 have fi gured out that PRDX1 safeguards the tumor-suppressive ... See full document
61
<p>Deep brain stimulation in Tourette’s syndrome: evidence to date</p>
... tive evidence from several case and series reports and some comparative studies together suggest that DBS is partially effective in alleviating symptoms in severe and medication- resistant cases of ...clinical ... See full document
16
<p>Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date</p>
... Lung Cancer Congress), that gather data from the three mentioned ...Lung Cancer (WCLC) 34,35 and may have been incorporated in the more recent report by Barlesi and coauthors, including a longer ... See full document
24
<p>RAP80 expression in breast cancer and its relationship with apoptosis in breast cancer cells</p>
... of breast were washed with ice-cold PBS and then lysed in lysis buffer containing 10 mM Tris (pH ...from breast cancer cell lines was extracted with TRIzol reagent (Thermo Fisher Scientific, Waltham, ... See full document
5
<p>Personalized medicine in breast cancer: pharmacogenomics approaches</p>
... cation, breast cancer is categor- ized into fi ve distinct molecular classes8 1, and 2 hormone receptor positive (luminal A and luminal B), 3 human epidermal growth factor receptor-2 (HER2-positive), 4 ... See full document
6
<p>Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date</p>
... Patient-reported outcomes: Overall, QOL improve- ment was signi fi cantly higher in the secukinumab trea- ted group compared to placebo (p<0.001). Patients treated with secukinumab also recorded a statistically ... See full document
9
Related subjects